Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | +10.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.31 | N/A | +10.14% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism about future developments. They emphasized their commitment to advancing their product pipeline.
Management expressed confidence in their ongoing projects and pipeline.
They highlighted the importance of upcoming trials and their potential impact.
Terns Pharmaceutical reported a wider-than-expected loss per share, which was better than some analysts anticipated. However, the lack of revenue details and no guidance update may have contributed to the stock's decline of 2.01%. Investors may be concerned about the company's future growth prospects without clearer financial direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CHEVRON CORP NEW
Aug 2, 2024